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Abstract 
Background: The majority of glioblastomas have aberrant receptor tyrosine kinase (RTK)/RAS/phosphoinositide 3 
kinase (PI3K) signaling pathways and malignant glioma cells are thought to be addicted to these signaling pathways 
for their survival and proliferation. However, recent studies suggest that monotherapies or inappropriate combina-
tion therapies using the molecular targeted drugs have limited efficacy possibly because of tumor heterogeneities, 
signaling redundancy and crosstalk in intracellular signaling network, indicating necessity of rationale and methods 
for efficient personalized combination treatments. Here, we evaluated the growth of colonies obtained from glioma 
tumor-initiating cells (GICs) derived from glioma sphere culture (GSC) in agarose and examined the effects of com-
bination treatments on GICs using targeted drugs that affect the signaling pathways to which most glioma cells are 
addicted.
Methods: Human GICs were cultured in agarose and treated with inhibitors of RTKs, non-receptor kinases or tran-
scription factors. The colony number and volume were analyzed using a colony counter, and Chou-Talalay combina-
tion indices were evaluated. Autophagy and apoptosis were also analyzed. Phosphorylation of proteins was evaluated 
by reverse phase protein array and immunoblotting.
Results: Increases of colony number and volume in agarose correlated with the Gompertz function. GICs showed 
diverse drug sensitivity, but inhibitions of RTK and RAF/MEK or PI3K by combinations such as EGFR inhibitor and MEK 
inhibitor, sorafenib and U0126, erlotinib and BKM120, and EGFR inhibitor and sorafenib showed synergy in different 
subtypes of GICs. Combination of erlotinib and sorafenib, synergistic in GSC11, induced apoptosis and autophagic 
cell death associated with suppressed Akt and ERK signaling pathways and decreased nuclear PKM2 and β-catenin 
in vitro, and tended to improve survival of nude mice bearing GSC11 brain tumor. Reverse phase protein array analysis 
of the synergistic treatment indicated involvement of not only MEK and PI3K signaling pathways but also others asso-
ciated with glucose metabolism, fatty acid metabolism, gene transcription, histone methylation, iron transport, stress 
response, cell cycle, and apoptosis.
Conclusion: Inhibiting RTK and RAF/MEK or PI3K could induce synergistic cytotoxicity but personalization is neces-
sary. Examining colonies in agarose initiated by GICs from each patient may be useful for drug sensitivity testing in 
personalized cancer therapy.
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Background
Malignant gliomas, including anaplastic astrocytoma 
and glioblastoma, are common primary tumors of the 
central nervous system, and characterized by aggressive 
cellular proliferation, diffuse infiltration, and resistance 
to cell death [1]. Diffuse infiltration of malignant glioma 
cells into adjacent brain parenchyma makes gross total 
removal by surgery difficult. Glioma cells that are resist-
ant to cell death-inducing stimuli cause recurrence after 
radiation therapy and chemotherapy. For these reasons, 
the outcome of patients with malignant gliomas is poor 
[1]. The tumorigenesis of malignant gliomas has been 
associated with a number of alterations in related genes 
causing functional loss of tumor suppressors includ-
ing PTEN, p53, NF1, RB1 or p16 proteins, and hyper-
function of oncogenic proteins such as EGFR, cyclin 
D1/3, E3 ubiquitin-protein ligase Mdm2, Mdm4, Met, 
Bcl-2, cyclin dependent kinase 4/6, PDGFRA and PI3K 
[2]. Among them, alterations of EGFR including gene 
amplification and activation mutations are observed 
in 40–57  % of malignant gliomas [2, 3]. The Cancer 
Genome Atlas (TCGA) Study also indicates that the vast 
majority of glioblastomas have aberrant RTK/RAS/PI3K 
signaling pathways [3]. Therefore, malignant glioma cells 
are thought to be addictive to these aberrant signaling 
pathways for their survival and proliferation, and thus 
targeting these signaling pathways has been thought to 
be effective on therapy of malignant gliomas [3]. How-
ever, a large number of clinical trials in which the tar-
geted therapies were examined for malignant glioma 
patients indicate that monotherapies using single anti-
cancer agents would have limited efficacy [4]. Recent 
studies indicate that inter- and intratumoral heteroge-
neities are major obstacles to the efficient targeted thera-
pies for solid tumors [2–5]. In addition, key signaling 
nodes to which multiple oncogenic signaling pathways 
converge might not be inhibited sufficiently by mono-
therapies or even by combination therapies because of 
unexpected redundancy or alterations of feedback in the 
signaling pathway network with complex crosstalk [6–8]. 
Therefore, it is necessary to find rationale of effective 
combination treatments and to optimize therapies to 
individual patients.
Glioma tumor-initiating cells (GICs) are thought to 
play a critical role in initiation, regrowth and recurrence 
of the tumor [1, 9]. Therefore, GICs need to be consid-
ered a target of glioma therapy, and it might be essential 
to evaluate effects of therapies on GICs from individual 
patients in order to predict the clinical relevance of the 
treatments and optimize therapy to the patients. In vitro 
screening of anticancer therapy has been done mainly 
by clonogenic assay because the effect of the therapy on 
clonogenicity of the tumor cells is thought to be asso-
ciated with the clinical therapeutic efficacy [10]. How-
ever, clonogenic assay using GICs has been a challenge 
because GICs aggregate in the stem cell culture media, 
and evaluation of the accurate tumor neurosphere/col-
ony number requires single cell culture system or semi-
solid matrix to prevent cell/colony aggregation. Single 
cell culture systems need large numbers of wells/plates 
and are not well suited for high-throughput screening 
of combination therapies [11]. Although colony forma-
tion assays of GICs or neural stem cells using gels have 
been reported, the growth of the colonies initiated by 
these cells in soft agar has not yet been well character-
ized [12–15]. In addition, a recent study suggested that 
proliferating cells with limited self-renewal capacity are 
more tumorigenic than glioma stem-like cells and thus 
therapeutic effects on these proliferating cells might be 
a better predictor for the in vivo efficacy [16]. Therefore, 
in drug sensitivity testing of gliomas, method by which 
we can evaluate both clonogenicity of GICs and cell 
proliferation of GICs and their descendant cells may be 
useful.
In this study, we cultured GICs in agarose and evalu-
ated the number and volume of the colonies that reflect 
clonogenicity and cell proliferation, respectively, using a 
colony counter GelCount. With this method, we exam-
ined efficiency of combination treatments using RTK 
inhibitors, non-receptor kinase inhibitors and transcrip-
tion factor inhibitors that affect the signaling pathways to 
which most glioma cells are thought to be addicted.
Methods
Antibodies and reagents
Erlotinib, lapatinib and sorafenib were purchased from 
LC laboratories (Woburn, MA), BKM120 was from 
Novartis (Basel, Switzerland), PD98059 and PP2 were 
from Selleck Chemicals (Houston, TX), U0126 and 
3-methyladenine (3-MA) were from Sigma-Aldrich (St. 
Louis, MO), c-Myc inhibitor II was from EMD Millipore 
Corporation (Billerica, MA). Imatinib mesylate was gen-
erously provided from Novartis. A polynuclear platinum 
BBR3610 was synthesized by Dr. Nicholas P Farrelle 
(Virginia Commonwealth University) [17]. WP1066, an 
inhibitor of tyrosine phosphorylated STAT3 and STAT5 
Keywords: Glioma, Stem cells, 3-D culture, Combination therapy, Synergistic, Autophagy, Receptor tyrosine kinase, 
Gompertz
Page 3 of 16Shingu et al. J Transl Med  (2016) 14:46 
was synthesized by Dr. Waldemar Priebe (The Univer-
sity of Texas MD Anderson Cancer Center) [18]. These 
reagents except for 3-MA, BBR3610 and imatinib were 
dissolved in DMSO (Sigma-Aldrich). 3-MA was dis-
solved in culture media, and imatinib and BBR3610 
were dissolved in PBS. Antibodies for Akt, AMPK, Atg5, 
Bad, c-Myc, EGFR, ERK, Met, poly-ADP ribose poly-
merase (PARP), pyruvate kinase isozyme M2 (PKM2), 
and ribosomal protein S6, or phosphorylated forms 
of Akt (Ser473), AMPK (Thr172), Bad (Ser136), EGFR 
(Tyr1173), ERK (Thr202/Tyr204), Met (Tyr1234/1235), 
and S6 (Ser235/236) were obtained from Cell Signaling 
Technology, Inc. (Danvers, MA). Antibodies for Bcl-2, 
Bcl-XL, β-catenin, Mcl-1, p53, and PTEN were obtained 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Anti-LC3B antibody was obtained from Novus Bio-
logicals, Inc. (Littleton, CO). Antibody for CD133 was 
obtained from Abcam plc (Cambridge, UK). Antibodies 
for lamin B and nestin were obtained from EMD Mil-
lipore. Antibodies for β-actin and vinculin were from 
Sigma-Aldrich.
Cell lines
Human malignant glioma cell line U87-MG was from 
American Type Culture Collection (Manassas, VA), and 
human malignant glioma cell lines LNZ308 and LN428 
were from Dr. Nicolas de Tribolet (Lausanne, Switzer-
land), during 2003–2007. These cells were maintained 
in DMEM (Life Technologies Corporation, Carlsbad, 
CA) containing 10 % FBS (Life Technologies), 100 units/
ml penicillin G, 100 μg/ml streptomycin, and 50 mg/ml 
l-glutamine (Life Technologies) in a humidified atmos-
phere containing 7  % CO2 at 37  °C. Human glioma 
tumor-initiating cells derived from glioma sphere culture 
were established by Dr. Frederick F Lang (The Univer-
sity of Texas MD Anderson Cancer Center) as described 
previously, in which GSC11 and GSC47 cells are non-
mesenchymal subtype and GSC2 and GSC20 cells are 
mesenchymal subtype [19, 20]. These cells are maintained 
in DMEM/Ham’s F12 medium (F12) (Life Technolo-
gies) containing 1× B27 supplement (Life Technologies), 
20  ng/ml EGF and 20  ng/ml basic FGF (Life Technolo-
gies), 100 units/ml penicillin G, 100 μg/ml streptomycin, 
and 50  mg/ml l-glutamine in a humidified atmosphere 
containing 7 % CO2 at 37 °C. Although the authentication 
of the purchased cell lines was not done by authors, DNA 
fingerprinting was done for testing cell line contamina-
tion using GenomeLab Human STR Primer Set accord-
ing to the manufacturer’s instruction (Beckman Coulter, 
Brea, CA). Infection by mycoplasma was examined by 
Mycoalert (Lonza, Basel, Switzerland) and infected cells 
were treated with BM cyclin (Roche Diagnostics, Indian-
apolis, IN).
3D cell culture in agarose gel
For analyses of number and volume (total biomass) of 
tumor spheres in agarose gel, culture media containing 
0.7 % agarose (Thermo Fisher Scientific, Waltham, MA) 
was used as the bottom layer, and culture media con-
taining 0.4–0.5  % agarose and tumor cells were placed 
in the middle layer, and then, culture media were added 
to the well in 96 or 24 well plates (Corning Incorporated, 
NY) [21]. Cells were seeded at 100, 150 and 200 cells in 
96 well plate as triplicate, or 250 and 500 cells in 24 well 
plate as duplicate. The final volumes of the bottom, mid-
dle and top layers for 96 well plate and 24 well plate were 
100, 100 and 50, and 500, 500, and 200  μl, respectively. 
After 4 h of seeding cells, culture media containing indi-
cated reagents were added and cells were further incu-
bated. Plates were scanned at the indicated time points 
in time course experiments or 12–14 days after addition 
of drugs in colony formation analysis, and number and 
total biomass of colonies larger than 40 μm in diameter 
were evaluated using GelCount colony counter system 
(Oxford Optronix Inc., UK).
Analysis of tumor growth
Surviving fraction in colony formation analysis and 
total biomass in volume analysis were calculated by the 
methods reported by Franken and Kajiwara, respectively 
[10, 21]. In vivo tumor growth in xenograft models can 
be described using an equation of Gompertz model as: 
V  =  V0 exp[(A/α)(1–exp[–αt])] where V0  =  initial vol-
ume, A and α = constant, V = volume at any time t [22]. 
In this study, colony number and total biomass were plot-
ted against time and examined by non-linear regression 
analysis against Gompertz growth curve where V0 = ini-
tial colony number and initial total biomass, respectively. 
Coefficients of determination (R2) were calculated using 
GraphPad Prism software (GraphPad Software Inc., San 
Diego, CA). Combination indices of drugs in colony for-
mation analysis were calculated by modified method 
of Chou and Talalay [23], and combination effect was 
thought to be synergistic when the combination index 
was less than 0.9. Tumor growth delay was calculated 
using the formula (Ti−C)/C where Ti and C were time 
(days) for treated and control tumors to reach double of 
total biomass at treatment, respectively [24].
Immunoblotting
After treatment with reagents, cells were harvested, 
washed with PBS, lysed in 50  mM Tris–HCl (pH 7.5), 
150 mM NaCl, 1 % Igepal-630, 1 mM EDTA, aprotinin, 
leupeptin, protease inhibitor and phosphatase inhibitor 
(Roche Diagnostics), and 1 mM PMSF and centrifuged at 
10,000×g at 4  °C for 20 min. The supernatant was used 
as the cell lysate. Extraction of nuclear and cytoplasmic 
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fractions of cells was done using Nuclear Extraction Kit 
(Sigma-Aldrich) according to the manufacture’s instruc-
tion. Ten-fifteen microgram of proteins were subjected to 
standard western blotting and the blots were quantified 
with ImageJ software (NIH, Bethesda, MD).
Survival analysis of nude mice with intracranial tumor
The intracranial tumor model was made using male 
nude mice (Experimental Radiation Oncology at M. D. 
Anderson Cancer Center) as described previously [25]. 
Through the screw guide, at a depth of 3.5  mm from 
the skull, 5  μl aliquots of 5 ×  105 GICs in DMEM/F12 
were inoculated at a rate of 1.0 μl/min. Mice were rand-
omized into four groups (4–8 mice per each group) and 
treatment was initiated 1  week after tumor implanta-
tion. Erlotinib and sorafenib were dissolved in solvent, 
OraPlus (Paddock Laboratories Inc., Minneapolis, MN), 
and administered at doses of 50 mg/kg of erlotinib and 
50  mg/kg of sorafenib orally three times a week for a 
total of twelve treatments. Mice of control group were 
treated with the solvent. All mouse studies were per-
formed in the veterinary facilities of The University of 
Texas M. D. Anderson Cancer Center in accordance with 
IACUC, state, federal, and ethical regulations for experi-
mental animal care.
Cell viability assay
For trypan blue dye exclusion assay, tumor cells were 
seeded at 2 × 104 cells per well in 24-well flat-bottomed 
plates and treated with reagents for indicated duration. 
Cells were dissociated by using accutase (Life Technolo-
gies) and the number of viable or dead cells (total >300 
cells) was counted in at least three different fields.
Quantification of apoptotic or non‑apoptotic cell death 
with annexin V and propidium iodide
After treatment with indicated reagents, cells were 
stained with FITC-conjugated annexin V and propid-
ium iodide for 15  min according to the manufacturer’s 
instruction (BD Biosciences, San Jose, CA), and then ana-
lyzed with FACSCalibur (Becton, Dickinson and Com-
pany, Franklin Lakes, NJ) using Cell Quest Pro software 
(Becton, Dickinson and Company).
Analysis of LC3 localization
A GFP-tagged LC3 (GFP-LC3) expression vector was 
kindly provided by Drs. N Mizushima (The University 
of Tokyo, Tokyo, Japan) and T Yoshimori (Osaka Uni-
versity, Suita, Japan) [26]. Tumor cells were seeded in 
24 well plates and transfected with GFP-LC3 expression 
vector using FuGENE HD Transfection Reagent (Roche 
Diagnostics). Cells were incubated overnight and treated 
with indicated reagents for 8  h. Cells were dissociated 
by using accutase, fixed with 4  % paraformaldehyde, 
mounted onto glass slides with VECTASHIELD Mount-
ing Medium (Vector Laboratories Inc., Burlingame, CA), 
and then examined using fluorescence microscope. The 
number of cells with or without GFP-LC3 punctate pat-
tern (total >300 cells) was counted in at least three differ-
ent fields.
RNA interference
siRNA was synthesized by Thermo Fisher Scientific 
(Dharmacon). The sequence of the siRNA targeting Atg5 
was CAACUUGUUUCACGCUAUAdTdT. siCONTROL 
Non-Targeting siRNA#2 was purchased from Thermo 
Fisher Scientific and used as control siRNA. Cells were 
transfected with siRNAs (3  μg) by electroporation using 
Nucleofector and a Cell Line Nucleofector® Kit T (Amaxa 
Biosystems, Gaithersburg, MD) according to the manu-
facturer’s instruction. After incubated overnight, cells 
were harvested, dissociated by using accutase, and seeded 
in 24 well plates for cell viability assay or 6 well plates for 
immunoblotting. After 3–4 h at 37 °C, cells were treated 
with reagents and subjected to the indicated assays.
Reverse phase protein array
Reverse phase protein array (RPPA) study was performed 
as described previously [7]. Briefly, serially diluted lysates 
were arrayed on nitrocellulose-coated slides (Grace Bio-
Labs, Inc., Bend, OR) by Aushon 2470 Arrayer (Aushon 
BioSystems, Billerica, MA). Total 5808 array spots were 
arranged on each slide including the spots correspond-
ing to positive and negative controls prepared from 
mixed cell lysates and dilution buffer, respectively. Each 
slide was probed with a validated primary antibody plus 
a biotin-conjugated secondary antibody. A panel of 171 
antibodies with a Pearson correlation coefficient between 
RPPA and western blotting of greater than 0.7 were used 
in RPPA study. The signal obtained was amplified using 
a Dako Cytomation–catalyzed system (Dako, Glostrup, 
Denmark) and visualized by DAB colorimetric reaction. 
The slides were scanned, analyzed, and quantified using 
a customerized-software Microvigene (VigeneTech Inc., 
Carlisle, MA) to generate spot intensity. Each dilution 
curve was fitted with a logistic model (“Supercurve Fit-
ting” developed by the Department of Bioinformatics 
and Computational Biology in The University of Texas 
MD Anderson Cancer Center, “http://bioinformatics.
mdanderson.org/OOMPA”). Results were normalized, 
transformed to base 2 logarithms and median centered, 
and the data from RPPA with three replicate samples 
were analyzed using two-way analysis of variance with an 
interaction term to assess whether the combined effect 
was significantly different from the sum of the individual 
effects.
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Gene expression analysis
Paired-end whole transcriptome sequencing of GIC cul-
tures was performed on the Illumina HiSeq platform 
after random priming and rRNA reduction. Each sam-
ple generated about 50 million paired-ends; each end 
was 75 bp in size. Short transcript reads were mapped to 
20,010 human protein coding genes in Ensembl reference 
transcriptome (ENSEMBL version 64). Downstream data 
analyses and RPKM (reads per kilobase per million reads) 
values were generated using pipeline for RNA sequenc-
ing data analysis (PRADA, PMID: 24695405) by involving 
Burroughs-Wheeler alignment, Samtools, and Genome 
Analysis Toolkit.
Statistical analysis
Paired Student’s t test (two-tailed) was used for compari-
son between two groups, and ANOVA with Tukey’s post 
hoc test was used for four groups. For the animal experi-
ment, pairs of Kaplan–Meier survival curves were com-
pared by the log-rank Mantel-Cox test using GraphPad 
Prism software. Differences were considered statistically 
significant when provided P was less than 0.05.
Results
Glioma cell growth in agarose
The Gompertz function has been used for tumor growth 
analysis because in vivo and in vitro tumor growth cor-
relates with the function [22, 27]. We evaluated cor-
relation between the Gompertz function and increases 
in colony number or total volume of the colonies (total 
biomass, TBM) of glioma cells in 3-dimensional (3D) cul-
ture system using agarose. As shown in Fig. 1a, increases 
of colony number and TBM in GICs correlated with the 
Gompertz function where coefficients of determination 
were larger than 0.99. Each cell line examined has specific 
values of A and α of the Gompertz equation (Additional 
file 1: Table S1).
Growth suppression of glioma cells by monotherapies 
and combination therapies
The TCGA study has revealed that 90  % of glioblasto-
mas have aberrant signaling in RTK/RAS/PI3K signaling 
pathways and thus molecules in these signaling path-
ways have been thought to be therapeutic targets [3]. 
However, successful treatments targeting these signaling 
pathways remain to be clarified [5–8]. Considering mul-
tiplicity of cancerous signaling pathways with complex 
crosstalk in a tumor cell, targeting relatively upstream 
molecule such as RTK that could affect multiple onco-
genic signaling pathways might be reasonable. To over-
come signaling redundancy, combined inhibition of 
multiple molecules that upregulate the same signaling 
pathway might be necessary. Recent study suggests that 
inhibition of relatively distal downstream molecule such 
as mTOR causes activation of the upstream oncogenic 
molecule such as Akt by decreasing feedback signaling 
and thus reduces efficacy of erlotinib in the combination 
therapy [8]. Therefore, we hypothesized that effective 
combination therapies consist of inhibitors of relatively 
upstream molecules including cellular membrane recep-
tors and their proximal downstream molecules, and then 
tested combination effects of RTK inhibitors and RAF/
MEK or PI3K inhibitors.
At first, we confirmed dose dependent effects of erlo-
tinib on colony formation in the agarose-based 3D cul-
ture system (Fig.  1b; Additional file  2: Figure  S1A) and 
then evaluated IC50 values in monotherapies of rea-
gents including RTK inhibitors erlotinib, lapatinib, and 
imatinib, and U0126 and BKM120 that suppress MEK 
and PI3K, respectively, in GICs with examination of 
phosphorylation or expression of EGFR, Met or PTEN 
protein or expression of genes related with RTKs, PI3K, 
RAS and p53/Rb pathway (Additional file 2: Figure S1B, 
Additional file  3; Table  1). Sorafenib is a multikinase 
inhibitor that suppresses VEGFR2, PDGFR, and RAF 
and thus was used as an RTK and RAF/MEK signaling 
inhibitor in this study. GSC11 cells, which are of the non-
mesenchymal subtype, showed the highest sensitivity to 
EGFR inhibitors, though expression or phosphorylation 
of EGFR was not the highest in this line amongst the 
examined cell lines and PTEN was not detected (Addi-
tional file  2: Figure  S1B; Table  1). GSC47 cells, which 
showed high EGFR expression and phosphorylation 
and intermediate levels of total and phophso-Met with-
out PTEN (Additional file  2: Figure  S1B) and are of the 
non-mesenchymal subtype, were relatively sensitive to 
erlotinib and lapatinib (Table 1). GSC20 cells, which had 
relatively low expression and phosphorylation levels of 
EGFR and low levels of total and phospho-Met and are 
of the mesenchymal subtype that is thought to be the 
most therapy-resistant subtype, showed relative resist-
ance to EGFR inhibitors (Additional file  2: Figure  S1B; 
Table  1) [3, 19]. GSC2 cells, which had high expression 
and phosphorylation levels of EGFR with PTEN expres-
sion and are of the mesenchymal subtype, also showed 
relative resistance to EGFR inhibitors (Additional file  2: 
Figure  S1B; Table  1). In the presence of 10  % FBS, U87 
cells, which have relatively high expression and low phos-
phorylation of EGFR, were also relatively resistant to 
EGFR inhibitors (Additional file 2: Figure S1B; Table 1). 
Therefore, it was difficult to predict sensitivity of glioma 
cells to EGFR inhibitors by status of EGFR, Met and 
PTEN despite previous encouraging reports, while cells 
with a mesenchymal profile tended to be more resistant 
to EGFR inhibitors than those with non-mesenchymal 
profile that is consistent with previous studies [28–32]. It 
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was also difficult to predict the sensitivity of the GICs to 
the other treatments by subtype or the expression levels 
of genes listed in Additional file 3.
Next, cells were treated with combinations that inhibit 
RTK and RAF/MEK or PI3K, and combination indices at 
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Fig. 1 Growth of glioma tumor-initiating cells (GICs) in agarose and growth suppression of GICs in vitro and in vivo by drug treatments. a Number 
(left panels) and volume [total biomass (TBM), right panels] of colonies of GSC11 (upper panels) and GSC20 (lower panels) cells cultured in agarose 
were plotted against time and the growth curves were fitted to the Gompertzian curve. The coefficients of determination between actual and fitted 
data (R2) >0.99 in all panels. b GSC11 and GSC20 cells were seeded in agarose and treated with erlotinib at day 0, and the colony number was evalu-
ated by using GelCount. Results shown are representative of three independent experiments. c, d GSC11 (c) and GSC20 (d) cells were seeded in 
agarose and treated with erlotinib and/or sorafenib after colony formation, and TBM was evaluated by using GelCount. Relative TBM to that at initia-
tion of the treatment was plotted against time. Broken lines were for evaluation of doubling time to calculate tumor growth delay. Results shown are 
representative of three independent experiments done in duplicate. e Nude mice were inoculated with GSC11 cells, and after 1 week erlotinib and/
or sorafenib were administered. The Kaplan–Meier survival curves were analyzed by log-rank test
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of RAF/MEK and PI3K in GICs, we also tested inhibitors 
of Src family kinases (PP2), STAT3/STAT5 (WP1066), 
and c-Myc (c-Myc inhibitor II) that are also related with 
RTK/RAS/PI3K signaling pathways, and a DNA cross-
linking agent (BBR3610) as a different class of drug that 
does not target specific signaling molecules [17, 18]. 
We expectedly found synergistic effects in combina-
tions that affect RTK and RAF/MEK or PI3K in multiple 
GIC lines (Table  2) while combinations of RTK inhibi-
tors with a Src inhibitor, transcription factor inhibi-
tors or DNA cross-linking agent were not synergistic 
(Additional file  1: Table S2). Lapatinib instead of erlo-
tinib or PD98059 instead of U0126 reproduced syner-
gistic effects in the combination treatments, confirming 
importance of inhibiting EGFR and MEK signaling path-
ways in the synergy (Table  2). We also examined com-
bination effects of U0126 and inhibitors of downstream 
molecules in EGFR signaling in order to examine if the 
synergy is reproduced by inhibiting downstream mol-
ecules instead of EGFR inhibition in GSC20 (Additional 
file  1: Table S2). However, neither of the combinations 
of U0126 with BKM120, PP2, WP1066, or c-Myc inhibi-
tor II was synergistic. In addition, combination of U0126 
and BKM120 was not synergistic in either of cell lines 
(Additional file  1: Table S2). Taken together, it appears 
that combined suppression of RTK and its distal down-
stream molecule such as transcription factor or inhibi-
tion of two parallel signaling molecules such as MEK 
and PI3K are not sufficient for synergistic cytotoxic-
ity. Instead combining an RTK inhibitor with a reagent 
that targets relatively proximal downstream molecules 
including RAF/MEK or PI3K induces synergistic antigli-
oma effects.
Combinations of EGFR inhibitor with sorafenib were 
synergistic in GSC11 cells, which are of the non-mesen-
chymal subtype, but not synergistic in GSC47 cells, which 
are also of the non-mesenchymal subtype (Table  2). In 
addition, GSC2 and GSC20, which are both of the mes-
enchymal subtype, showed different sensitivities to com-
bination therapies (Table  2). These results indicate that 
GICs show diverse sensitivity to therapies and that per-
sonalization is necessary for therapy even in the same 
subtype of glioma.
Next we evaluated the combined effect of erlotinib 
and sorafenib on the total biomass in time course study. 
Both tumor growth delay analysis and combination 
Table 1 IC50 values of drugs in glioma tumor-initiating cells and U87 cultured in agarose
Data are means ± 95 % confidence intervals of at least two independent experiments
 NE Not examined, NA Not available, Myc II c-Myc inhibitor II
Drugs GSC11 GSC47 GSC20 GSC2 U87
Receptor tyrosine kinase inhibitors
 Erlotinib (μM) 0.11 ± 0.03 0.49 ± 0.15 0.82 ± 0.34 3.08 ± 0.55 3.72 ± 0.60
 Lapatinib (μM) 0.64 ± 0.22 1.86 ± 0.16 4.39 ± 1.08 3.04 ± 0.99 7.01 ± 2.20
 Sorafenib (μM) 2.59 ± 0.50 1.09 ± 0.44 2.21 ± 0.16 3.51 ± 0.25 5.24 ± 0.01
 Imatinib (μM) 6.37 ± 0.90 NE 11.0 ± 1.57 6.28 ± 2.24 3.24 ± 2.10
Non-receptor kinase inhibitors
 U0126 (μM) 14.0 ± 4.72 18.0 ± 3.25 4.69 ± 1.33 11.0 ± 0.25 11.1 ± 5.35
 BKM120 (μM) 0.41 ± 0.05 0.46 ± 0.21 0.36 ± 0.05 0.49 ± 0.10 0.59 ± 0.21
 PP2 (μM) 1.93 ± 0.50 NE 6.39 ± 2.46 4.33 ± 0.34 NA > 20
Transcription factor inhibitors
 WP1066 (μM) 2.46 ± 0.62 NE 1.55 ± 0.13 1.96 ± 0.13 1.59 ± 0.40
 Myc II (μM) 22.3 ± 3.57 NE 13.3 ± 1.50 19.0 ± 3.47 27.0 ± 5.68
DNA cross-linking agent
 BBR3610 (nM) 46.6 ± 23.0 NE 87.3 ± 33.5 117.3 ± 71 1.46 ± 1.26
Table 2 Synergistic combinations of targeted drugs in gli-
oma tumor-initiating cells
Chou and Talalay combination indices (CI) are shown as means ± 95 % 
confidence intervals of at least two independent experiments. Synergistic 
interactions were confirmed by three independent experiments. According to 
the original study by Chou and Talalay, CI <1, = 1; and >1 indicate synergistic, 
additive, and antagonistic, respectively. In this study, combination effect was 
thought to be synergistic when CI was less than 0.9
 NE Not examined
Drugs GSC11 GSC47 GSC20 GSC2
Erlotinib + Sorafenib 0.85 ± 0.23 1.30 ± 0.16 1.21 ± 0.26 1.04 ± 0.24
Lapatinib + Sorafenib 0.82 ± 0.27 1.17 ± 0.40 1.18 ± 0.05 1.32 ± 0.06
Erlotinib + U0126 0.98 ± 0.24 2.14 ± 0.75 0.73 ± 0.08 0.52 ± 0.31
Erlotinib + PD98059 NE NE 0.79 ± 0.17 NE
Lapatinib + U0126 NE NE 0.86 ± 0.12 NE
Erlotinib + BKM120 1.16 ± 0.19 NE 1.04 ± 0.24 0.71 ± 0.05
Sorafenib + U0126 0.67 ± 0.13 0.73 ± 0.09 1.20 ± 0.59 0.56 ± 0.30
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index at 1  week after treatment indicated synergistic 
effects in GSC11 cells, while tumor growth delay analy-
sis showed synergy but combination index indicated 
only additivity in GSC20 cells (Fig.  1c, d; Additional 
file 1: Table S3). Considering these findings in total bio-
mass analysis together with those from the colony for-
mation study (Table 2), we concluded that GSC11 cells 
are sensitive to combination of erlotinib with sorafenib, 
and evaluated the effects of the combination therapy 
on nude mice bearing brain tumor (Fig. 1e). Although 
analyses of the survival curves and the median sur-
vival time did not indicate statistically significant dif-
ference, the median survival time of the combination 
group (83d) was remarkably improved by the combina-
tion treatment compared with those of control (74.5d), 
erlotinib (74d) and sorafenib (70d) groups, even with 
the doses that did not improve the survival in the 
monotherapies.
Combination treatment‑induced apoptotic and autophagic 
cell death
Analysis of cell death revealed that combination treat-
ment with erlotinib and sorafenib significantly increased 
cell death in GSC11 but not in GSC20 cells (Fig. 2a, b). 
Other synergistic combinations identified in the col-
ony formation assay, such as U0126 and sorafenib in 
GSC11 or erlotinib and U0126 in GSC20, also increased 
cell death significantly (Fig.  2c, d). In immunoblot-
ting, the synergistic combination treatments increased 
both microtubule-associated protein 1 light chain 3B-II 
(LC3B-II) and phosphorylated AMPK 8  h after treat-
ment, and induced cleavage of PARP or decrease of 
full length PARP 48  h after treatment, indicative of 
autophagy and apoptosis, respectively (Fig.  3a). Those 
treatments also decreased anti-cell death proteins such 
as Bcl-2 and Bcl-XL (Fig.  3a). Increase of autophagic 
and apoptotic cells by combination of erlotinib with 
sorafenib was confirmed by transient GFP-LC3 expres-
sion experiments and annexin V staining, repectively 
(Figs.  3b, c and 4a). Inhibition of autophagy by 3-MA 
increased apoptotic cell death but decreased non-
apoptotic and total cell death (Fig.  4a–c). Knockdown 
of Atg5 also decreased total cell death induced by the 
combination treatment (Fig.  4d). These results indi-
cate that autophagy in synergistic combination thera-
pies is cytokilling. We also examined CD133 and nestin 
that are thought to be marker proteins for glioma cell 
stemness (Fig. 3a) [9]. The synergistic combination treat-
ments effectively reduced the amounts of those proteins 
48 h after treatment. Taken together, it appears that the 
combination therapies induce synergistic cytotoxicity 
through apoptosis and autophagic cell death, and effi-
ciently decrease glioma cells with stemness.
Combination treatment‑induced alterations in signaling 
pathways
We did reverse phase protein array (RPPA) analysis to 
examine alterations in a panel of 171 signaling related 
proteins (Additional files 4, 5) in GSC11 cells 60  min 
after treatment with erlotinib and sorafenib. As shown in 
Additional file  1: Table S4, proteins on which the com-
bination treatment induced a statistically significant 
synergistic effect included phosphorylated proteins that 
are related with PI3K/Akt or RAS/MEK/ERK signaling 
pathways. In addition, 16 proteins that are not directly 
associated with downstream of PI3K/Akt or MEK/ERK 
signaling pathways were altered toward tumor suppres-
sive direction, including proteins related with apopto-
sis (Bax, caspase 7), cell cycle (CDK1, Chk1, stathmin), 
fatty acid metabolism (SCD1), gene transcription (Smad, 
STAT5a, TTF1), glucose metabolism (G6PD, GAPDH), 
histone methylation (SETD2), iron transport (TFRC), 
stress response (NDRG1), or tyrosine kinase (c-Met, 
Lck) (Additional file 5). These results suggest that inhibi-
tion of RTK affects various cancerous signaling pathways 
that might not be reproduced by suppressing small num-
ber of downstream molecules even though they might be 
signal converging molecules. We confirmed remarkable 
decreases in phosphorylated forms of Akt, S6 and ERK 
in GSC11 cells 60 min after treatment with erlotinib and 
sorafenib in immunoblotting (Fig.  5a). Another syner-
gistic combination therapy in GSC11 cells, U0126 and 
sorafenib, also inhibited phosphorylations of Akt and 
S6 (Fig.  5a). These combination treatments decreased 
nuclear PKM2 and β-catenin 24  h after treatment 
(Fig. 5b). However, combination of erlotinib with U0126, 
which was synergistic in GSC20, did not decrease phos-
phorylated Akt or S6 remarkably or nuclear PKM2 or 
β-catenin while phospho-ERK was efficiently decreased 
by U0126 alone in GSC20 cells (Fig. 5a, b). These results 
indicate that immediate inhibition in at least Akt sign-
aling and subsequent decreases in nuclear PKM2 and 
β-catenin are associated with the synergistic cytotoxicity 
in GSC11 cells but there is intertumoral heterogeneity in 
alterations of molecules that are downstream to the tar-
gets of the synergistic treatments.
Discussion
Among several mathematical representations of tumor 
growth, the Gompertz model has been used in studies 
of experimental therapies because it has been shown to 
correlate not only with in  vitro cell number and tumor 
sphere volume but also with in  vivo tumor weight and 
volume in previous studies using conventional cell lines 
[22, 27, 33–36]. Our study is, as far as we know, the first 
showing that both number and total volume of colonies 
of GICs cultured in agarose correlate with the Gompertz 
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function. Correlation of the Gompertz curve with the 
in vitro tumor growth curves in our study might indicate 
that tumor growth pattern in this culture system resem-
bles in vivo tumor growth, though the time scale would 
be different. One of the advantages of 3D culture with gel 
is that aggregation of cells or colonies can be prevented 
and thus we can evaluate both accurate colony num-
ber that is thought to reflect clonogenicity of GICs and 
volume of the colonies formed not by cell aggregation but 
by cell proliferation. In addition, approximately 20–60 
colonies are formed in 1 well of 96-well plate that might 
enable us to analyze the clonogenicity with lower number 
of wells and plates but higher statistical power than single 
cell culture system. We found that combination therapy 
of erlotinib and sorafenib in GSC11 cells was synergis-
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Fig. 2 Increases of cell death by combination treatments in glioma tumor-initiating cells. GSC11 (a and c) and GSC20 (b and d) cells were treated 
with vehicle (control) or indicated drugs for indicated periods of time and analyzed with trypan blue dye exclusion assay to calculate percentage 
of dead cells. Data are expressed as the means of at least two independent experiments done in duplicate. Error bars are 95 % confidence intervals. 
*means p < 0.05 in ANOVA and Tukey’s post hoc test in comparison of combination treatment group with any of the other groups
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Fig. 3 Induction of autophagy and apoptosis, and decrease of glioma stemness marker proteins by synergistic combination treatments in glioma 
tumor-initiating cells. a Cells were treated with vehicle as control (C), erlotinib (E), sorafenib (S), U0126 (U) and combinations for indicated duration, 
and 10 μg of extracted proteins in each sample were subjected to immunoblotting using indicated antibodies to detect total or phosphorylated 
(p-) proteins. Concentrations of drugs were as follows: erlotinib; 0.6 μM for GSC11 and 6 μM for GSC20, sorafenib; 4 μM for GSC11, U0126; 10 μM for 
GSC11 and 20 μM for GSC20. β-actin was examined as loading control. Results shown are representative of at least two independent experiments. 
b and c GSC11 cells with transfection of GFP-LC3 were treated with vehicle (control), 0.6 μM erlotinib, 4 μM sorafenib or the combination for 48 h. b 
Scale bar is 5 μm. c Cells with punctate pattern of GFP-LC3 were counted as autophagic cells. Data shown are the means of two independent experi-
ments. *means significant difference (p < 0.05) between any two of the four groups by ANOVA and Tukey’s post hoc analysis
Page 11 of 16Shingu et al. J Transl Med  (2016) 14:46 
in vitro using the 3D culture method, and that the in vivo 
combination therapy showed tendency of improvement 
of survival by the combination therapy, indicating cor-
relation in the therapeutic efficacy between this in vitro 
assay system and in vivo experimental model. Although 
we used minimal doses of erlotinib and sorafenib that did 
not improve the median survival as monotherapies, the 
combination treatment tended to improve the survival, 
suggesting supra-additive effect by the combination ther-
apy in vivo. Since the maximum tolerated doses of erlo-
tinib and sorafenib in combination therapy in mouse are 
higher, efficiency of the combination therapy might be 
improved by increasing doses of the drugs [37].
Based on the TCGA study that showed possible addic-
tion of glioblastoma cells to several signaling pathways, 
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Fig. 4 Decrease of combination therapy induced cell death by inhibiting autophagy in GSC11 cells. a–d GSC11 cells with 3-methyladenine (3-MA) 
treatment (a, b and upper panel of d) or with transfection of siRNA targeting Atg5 (siAtg5) (c and lower panel of d) were treated with vehicle (con-
trol), 0.6 μM erlotinib, 4 μM sorafenib or the combination for 8 h for immunoblotting using anti-LC3B or anti-Atg5 antibodies (d), or 72 h for apopto-
sis assay using propidium iodide (PI), annexin V (AV), and flow cytometer (a-i–a-iii ) or trypan blue dye exclusion assay (b and c). (a-i) Early apoptosis; 
PI (−) with AV (+). (a-ii) Non-apoptotic cell death; PI (+) with AV (−). (a-iii) Total cell death; PI (+). a–c Data are expressed as the means of three 
independent experiments. *means p < 0.05 in ANOVA and Tukey’s post hoc analysis comparing combination treatment group with others. p values 
shown were calculated by student’s paired t test. Error bars are 95 % confidence intervals. d Inhibitory effects of 3-MA and siAtg5 on LC3B-II increase 
was confirmed by immunoblotting. β-actin was examined as loading control. Results shown are representative of two independent experiments
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Fig. 5 Alterations of signaling pathways by synergistic combination treatments in glioma tumor-initiating cells. a Cells were treated with vehicle 
as control (C), erlotinib (E), sorafenib (S), U0126 (U), and combinations for indicated duration, and 10 μg of extracted proteins in each sample were 
subjected to immunoblotting using indicated antibodies to detect total or phosphorylated (p-) proteins. Concentrations of drugs were as follows: 
erlotinib; 0.6 μM for GSC11 and 6 μM for GSC20, sorafenib; 4 μM for GSC11, U0126; 10 μM for GSC11 and 20 μM for GSC20. β-actin was examined 
as loading control. b GSC11 or GSC20 cells were treated with indicated reagents for 24 h and 10 g of extracted nuclear or cytoplasmic proteins in 
each sample were subjected to immunoblotting using anti-PKM2 and anti-β-catenin antibodies. Lamin B and vinculin were examined as loading 
controls of nuclear proteins and cytoplasmic proteins, respectively. Relative values of blots of PKM2 and β-catenin in treatment groups to control 
were calculated using ImageJ
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treatments using RTK inhibitors, non-receptor kinase 
inhibitors, and transcription factor inhibitors [3]. Since 
clinical trials of targeted therapies for malignant glioma 
patients have shown that monotherapies and inappropri-
ate combination therapies have limited efficacy, finding 
rationale of efficient combination treatments is necessary 
[4, 8]. This is the first report showing synergistic effects of 
combinations of EGFR inhibitor with sorafenib, sorafenib 
with U0126, EGFR inhibitor with MEK inhibitor, and 
erlotinib with BKM120 on GICs beyond their subtype. 
Among these synergistic treatments, combination of 
erlotinib with sorafenib was reported to be synergistic in 
colorectal and lung cancer cells [37, 38]. Although U0126 
was reported to be protective against sorafenib-induced 
cytotoxicity in hepatocellular carcinoma (HCC) cells, 
combination of sorafenib with another MEK inhibitor 
CI-1040 was synergistic associated with increased Bim 
in HCC cells [39, 40]. Although synergistic effect by erlo-
tinib and U0126 has not been reported, a MEK inhibitor 
was shown to decrease resistance of non-small cell lung 
cancer (NSCLC) cells to EGFR inhibitors [41]. Similarly, 
although synergistic effect by erlotinib and BKM120 has 
not been reported, combinations of erlotinib and PI3K/
mTOR inhibitors showed synergistic cytotoxicity in cells 
of prostate cancer, NSCLC and ovarian cancer in previ-
ous studies [42–44]. Findings in these sporadic studies 
are consistent with those in our systematic evaluation 
that show significance of combined inhibition of RTK 
with PI3K or RAF/MEK. Importantly, inhibition of MEK 
and PI3K did not induce synergistic effect in our study. 
Instead, RPPA study indicates that synergistic combina-
tion therapy could affect multiple signaling pathways 
including not only RAS/ERK and PI3K/Akt but also other 
pathways that are critical for tumor cell survival and pro-
liferation. Therefore, the rationale for the effective combi-
nation treatments of GICs might be suppression of both 
an RTK that activates multiple signaling pathways which 
form complex signaling network and RAF/MEK or PI3K 
that could play critical roles in the redundancy of the key 
signaling pathways.
However, we found significant variations in drug sen-
sitivity and intracellular signaling pathways between 
GICs. Even GSC2 and GSC20 cells, which are classified 
into the same subtype of gliomas, showed different sen-
sitivity to most of the mono- and combination thera-
pies. MEK/ERK/NFκB signaling induces translocation 
of PKM2 into nucleus where PKM2 binds to β-catenin 
that activates transcription of genes related with cell 
proliferation including c-Myc and CDK1. [45–47]. 
Nuclear PKM2 also phosphorylates spindle checkpoint 
protein Bub3 resulting in mitosis progression [48]. 
Nuclear β-catenin regulates transcription of Bcl-2 and 
Mcl-1. [49]. Therefore, alterations of these molecules in 
GSC11 cells induced by combination of erlotinib with 
sorafenib were consistent with the increased cytotoxic-
ity by the combination therapy. However, GSC20 cells 
responded to combination of erlotinib with sorafenib 
in a different manner from that of GSC11 cells regard-
ing both cell death (Fig.  3b) and signaling molecules 
(data not shown). In addition, phosphorylated Akt and 
ERK in GSC2 cells treated with erlotinib and sorafenib 
also showed different alteration patterns from those in 
GSC11 or GSC20 (data not shown). Given that intratu-
moral heterogeneity contributes to therapy resistance 
and recurrence of the tumor in a patient, our findings 
indicate that intertumoral heterogeneity of GICs in 
sensitivity to cytotoxic stimuli associated with diverse 
alterations in intracellular signaling pathways could 
be another reason for the failure of the “one-size-fit-
all” designed treatment for malignant glioma patients 
[5, 8, 50]. In several types of cancers, novel classifica-
tions based on biomarkers or profiling are providing 
actionable and critical information to make clinical 
decisions [51]. In glioma patients, there is a possibil-
ity that a small number of molecular features such as 
CpG island methylation phenotype (G-CIMP) or IDH1 
mutation status could be useful for prediction of the 
outcome [32, 52]. In addition to these factors, different 
status of several key molecules could alter dependency 
of GICs on the key signaling pathways or crosstalk/
feedback network [3, 14, 28, 29, 41, 53]. In this study, 
we found that at least GSC2, GSC11 and GSC20 are 
neither G-CIMP nor IDH1 mutant subtype (data not 
shown) and have different gene expression patterns 
regarding RTKs, PI3K, RAS and Rb pathways that could 
induce the diversity in the drug sensitivity of the GICs 
even in the same subtype (Additional file  3). However, 
our findings as well as previous studies indicate diffi-
culty in predicting sensitivity of glioma cells to specific 
treatment by alterations in small number of genes or 
proteins [30, 54]. These findings have been fueling pro-
filing approach using large data set [19, 32, 55]. How-
ever, the current subtype classification of gliomas might 
not be sufficient for selecting the best treatment for 
patients while certain extent of the effectiveness was 
found [19]. Therefore, it is necessary to establish a more 
effective personalized optimization method for glioma 
therapy. Although hypothesis-driven studies with omic 
analyses that attempt to predict sensitivity of tumors 
are intensely performed, unpredictability of cancer cell 
response to specific treatment has not yet been over-
come. Empiric approaches such as treatment sensitivity 
testing using cultured tumor cells obtained from each 
patient have also been studied but have not yet signifi-
cantly improved outcome of glioma patients [56, 57]. 
In this study, we showed that synergistic combination 
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treatments for different cell lines with diverse drug sen-
sitivity can be efficiently identified by examining the-
ory-driven combinations, which are RTK inhibitors and 
RAF/MEK or PI3K inhibitors, indicating that integra-
tion of rationale-based candidate selection with empiric 
screening approach is useful to optimize therapy for 
individual patients against intertumoral heterogeneity.
Role of autophagy in efficient combination therapy
Among the synergistic combination treatments, we 
focused on the combination of erlotinib and sorafenib 
because clinical trials for patients with tumors includ-
ing malignant gliomas to examine efficacy of the combi-
nation therapy were ongoing when we started this study 
[50, 58]. This is the first report showing autophagic cell 
death induced by the combination treatment. Autophagy 
is thought to be a cellular process for homeostasis and 
adaptation to stress and is thus cytoprotective mecha-
nism [59]. However, unregulated excessive autophagy is 
known to be cytotoxic, inducing autophagic cell death 
[59]. Results in this study indicate that monotherapy of 
erlotinib might induce cytoprotective autophagy but the 
combination of erlotinib and sorafenib causes cell-killing 
autophagy. Autophagy might be associated with cellu-
lar senescence whose role in antitumor therapy has not 
yet been established because the senescence in tumor 
cells can contribute to not only therapy resistance but 
also growth suppression or sensitization to therapy [60–
62]. While these findings suggest the complex role of 
autophagy in tumor therapy, our observation might indi-
cate the potential of combination therapies that induce 
autophagy-related remarkable cytotoxicity in tumor-ini-
tiating cells.
Conclusion
We found that growth of GICs in agarose gel corre-
lates with the Gompertz function. Combination treat-
ments that affect RTKs and the proximal downstream 
molecules RAF/MEK or PI3K induce synergistic cyto-
toxicity in different GICs that show diversity in drug 
sensitivity. Among these combination treatments, com-
bination of erlotinib with sorafenib induces apoptotic 
and autophagic cell death associated with attenuated 
Akt and ERK signaling, decreased nuclear PKM2 and 
β-catenin and affected Bcl-2 family proteins in GSC11 
cells in vitro, and tends to improve survival of the brain 
tumor xenografts. Although sensitivity of GIC lines to 
anticancer agents is diverse, the rationale for efficient 
combination therapy is thought to be inhibition of both 
RTK and RAF/MEK or PI3K. This rationale and the 
method in this study could be useful for personalized 
drug screening using GICs from each patient to opti-
mize targeted therapy for glioma patients.
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